CDKN2A and cancer: The protein product of CDKN2A impedes the degradation of tumor suppressor protein p53 by interacting with its E3 ubiquitin-protein ligase MDM2, and mutation of CDKN2A can lead to aberrant cell cycle progression in multiple types of cancer [50].